About the Journal
Translational Lung Cancer Research
Translational lung cancer research (TLCR, Transl Lung Cancer Res, Print ISSN 2218-6751; Online ISSN 2226-4477) publishes articles that describe new findings in the field of translational research in lung cancer, provides current and practical information on diagnosis, prevention and clinical investigations of lung cancer. Specific areas of interest include, but not limited to, multimodality therapy, markers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to lung cancers. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to lung cancers. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field, while providing practical up-to-date information on diagnosis, prevention, and treatment of lung cancer. The journal features a distinguished editorial board, which brings together a team of highly experienced specialists in lung cancer treatment and research. The diverse experience of the board members allows our editorial panel to lend their expertise to a broad spectrum of lung cancer subjects. The entire submission and review process are managed through OJS system, an electronic system, which provides an efficient way and ensures a rapid turnaround of papers submitted for publication. The goal of the Journal is to provide readers with a new, well-constructed, informative, and educational journal. The Official Publication of:
- Society for Translational Cancer Research (STCR)
TLCR is endorsed by Spanish Lung Cancer Group and Bonnie J. Addario Lung Cancer Foundation (ALCF). TLCR is indexed by PubMed/PubMed Central (PMC) and the Chemical Abstracts Service (CAS) Databases.